Brendan Teehan - 06 Jan 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, COO, Head of Commercial
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
06 Jan 2022
Transactions value $
-$12,401
Form type
4
Filing time
10 Jan 2022, 17:25:32 UTC
Previous filing
19 Nov 2021
Next filing
25 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +1.29K +123.65% 2.33K 06 Jan 2022 Direct F1, F2
transaction ACAD Common Stock Sale -$12.4K -538 -23.13% $23.05 1.79K 06 Jan 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -1.29K -33.32% $0.00 2.57K 06 Jan 2022 Common Stock 1.29K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 233 shares of the Issuer's common stock acquired by the reporting person on November 15, 2021 pursuant to an employee stock purchase program.
F3 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4 The restricted stock units vest in four equal annual installments beginning January 6, 2021.